Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

NCT07008469 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.

NCT NCT07008469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07008469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Lead sponsor
Avidity Biosciences, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
June 26, 2025
Completion date
October 31, 2030
Enrollment
199 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

dm1, myotonia, myotonic disorders, myotonic dystrophy, myotonic dystrophy 1, myotonic dystrophy type 1, steinert disease, steinert myotonic dystrophy